Results 141 to 150 of about 119,167 (297)

Glucagon-like peptide-2 protects the gastric mucosa via regulating blood flow and metabolites. [PDF]

Front Endocrinol (Lausanne), 2022
Zhang J, Ning J, Hao X, Han X, Fu W, Gong Y, Meng Q, Ding S, Zhang J.   +8 more
europepmc   +1 more source

Potential determinants of low circulating glucagon-like peptide 2 concentrations in Zambian children with non-responsive stunting. [PDF]

Exp Physiol, 2023
Besa E, Tembo MJ, Mulenga C, Mweetwa M, Choudhry N, Chandwe K, Storer C, Head R, Amadi B, Haritunians T, McGovern D, Kwenda G, Peiris M, Kelly P.   +13 more
europepmc   +1 more source

Glucagon-like Peptide 2 (GLP-2) [PDF]

, 2004
Julie Lovshin, Daniel J. Drucker
openaire   +1 more source

Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists

iNew Medicine, EarlyView.
Chao Xue
wiley   +1 more source

Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure. [PDF]

World J Gastroenterol, 2022
Pizzoferrato M, Puca P, Ennas S, Cammarota G, Guidi L.   +4 more
europepmc   +1 more source

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

Med Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian, Yan Wang, Lei Peng, Min Zhao, Hao Tian, Zhenyu Wu, Aiqi Tang, Minghao Sun, Yi Zhang, Xiaowei Qi   +12 more
wiley   +1 more source

Conformational Dynamics of Glucagon-like Peptide-2 with Different Electric Field. [PDF]

Polymers (Basel), 2022
Su J, Sun T, Wang Y, Shen Y.
europepmc   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, EarlyView.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Exenatide extended-release; clinical trials, patient preference, and economic considerations

Patient Preference and Adherence, 2013
Sheila A DoggrellSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, AustraliaAbstract: Type 2 diabetes remains an escalating problem worldwide, despite a range of treatments being available.
Doggrell SA
doaj  

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects. [PDF]

Clin Drug Investig, 2022
Agersnap MA, Sonne K, Knudsen KM, Knudsen CB, Berner-Hansen M.   +4 more
europepmc   +1 more source